Relapse leukemia treatment following allogeneic HSCT by CIK

Relapse leukemia treatment following allogeneic HSCT by recipient derived donor origin CIK

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-11001348

Enrollment

Unknown

Registered

2011-06-03

Start date

2011-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actue leukemia

Interventions

Group A:Chemothrapy+DLI

Group B:Chemothrapy+CIK

Group C:Chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. the relapsed leukemia is confirmed by cytomytric and cytogenetic tests as recipient origin; 2. Patients must have adequate renal function with a serum creatinine of 50 ml/min; 3. Patients must have adequate liver function with a total bilirubin < 2 mg/dl or transaminases < 3 times the upper limit of normal; 4. HIV negative; 5. Patients must sign informed consent prior to initiation of any study-related treatments; 6. The mononuclears in the peripheral blood of patients should nearly be donor type.

Exclusion criteria

Exclusion criteria: 1. LVEF 2 mg/dl; 4. Creatinine > 2 mg/dl; 5. Pregnancy; 6. Patients positive for HIV; 7. Patients have the active ,uncontrolled infection; 8. The mononuclears in peripheral blood are not totally donor type.

Design outcomes

Primary

Measure	Time frame
leukemia free survival;GVHD;over all survival;	—

Countries

China

Contacts

Public ContactYong You

youunion@126.com+86 13907146261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026